论文部分内容阅读
目的:探讨保留膀胱术+膀胱内灌注化疗+静脉化疗治疗浸润性膀胱癌的临床疗效及其应用价值。方法:2007年1月-2012年8月期间行经尿道膀胱肿瘤电切术或膀胱部分切除术的25例肌层浸润性膀胱癌(T2-3N0M0)的患者,给予静脉化疗加膀胱灌注化疗,GC化疗方案(吉西他滨1 000mg/m2,第1天,静脉滴注;顺铂70mg/m2,第2-4天,静脉滴注,每3周重复),共4-6个疗程;常规膀胱灌注化疗,药物为吡柔比星。结果:25例例患者均获得随访,随访12-68个月,平均34个月,20例(80%)患者无复发及转移,5例(20%)患者复发,3例复发患者给予全膀胱切除术,2例患者给予介入治疗或放疗,1例患者死亡,化疗副反应均可耐受。结论:保留膀胱手术后确诊的局限性浸润性膀胱癌的患者,采用静脉化疗治疗+膀胱内灌注化疗的联合治疗方法,能明显的提高疗效,有效地减少肿瘤的复发,提高了患者的生活质量,患者易于接受,值得进一步探讨。
Objective: To investigate the clinical efficacy and its clinical value of reserving bladder surgery + intravesical chemotherapy + intravenous chemotherapy in the treatment of invasive bladder cancer. METHODS: Twenty-five patients with myometrial invasive bladder cancer (T2-3N0M0) undergoing transurethral resection of the bladder tumor or partial partial resection of the bladder between January 2007 and August 2012 were treated with intravenous chemotherapy plus intravesical chemotherapy plus GC Chemotherapy regimen (Gemcitabine 1 000mg / m2, day 1, intravenous infusion; cisplatin 70mg / m2, 2-4 days, intravenous infusion, repeated every 3 weeks), a total of 4-6 courses; conventional intravesical chemotherapy The drug is pirarubicin. Results: Twenty-five patients were followed up for 12-68 months with an average of 34 months. No recurrence or metastasis was found in 20 patients (80%), 5 patients (20%) were relapsed, and 3 patients with recurrent bladder disease Excision, 2 patients were given interventional therapy or radiotherapy, 1 patient died, chemotherapy side effects can be tolerated. CONCLUSIONS: The combination of intravenous and intravesical chemotherapy in patients with localized invasive bladder cancer diagnosed after bladder surgery can significantly improve efficacy, reduce tumor recurrence, and improve patient quality of life , Patients are easy to accept, it is worth further study.